Stock Scorer

Vicore Pharma Holding AB (VICO.ST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in SEK. Every figure as a table ›

Revenue Annual

0 FY21: 0 FY22: 0 FY23: 0 FY21 FY22 FY23

Gross Profit Annual

0 FY21: 0 FY22: 0 FY23: 0 FY21 FY22 FY23

Operating Income Annual

-450M -300M -150M 0 150M 300M 450M FY21: -294.8M FY22: -290.7M FY23: -321.5M FY21 FY22 FY23

Net Income Annual

-450M -300M -150M 0 150M 300M 450M FY21: -296.5M FY22: -288.4M FY23: -310.9M FY21 FY22 FY23

Operating Cash Flow Annual

-300M -150M 0 150M 300M 450M FY21: -265.2M FY22: -299.9M FY23: -249.6M FY21 FY22 FY23

EPS Annual

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 FY21: -4.25 FY22: -3.99 FY23: -3.22 FY21 FY22 FY23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for VICO.ST: Cost of Revenue, Free Cash Flow, Shares Outstanding. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.